Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia

Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia

IntroductionChronic lymphocytic leukemia (CLL) cells are metabolically flexible and adapt to modern anticancer treatments. Bruton tyrosine kinase (BTK) and B-cell lymphoma-2 (BCL-2) inhibitors have been widely used to treat CLL, but CLL cells become resistant to these treatments over time. CB-839 is...

Full description

Bibliographic Details
Main Authors: Natalia Timofeeva, Mary L. Ayres, Natalia Baran, Janice M. Santiago-O’Farrill, Gamze Bildik, Zhen Lu, Marina Konopleva, Varsha Gandhi
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Oncology
Subjects:
CLL - chronic lymphoblastic leukemia
BTK - Bruton’s tyrosine kinase
Bcl-2 inhibitor
Mcl-1 inhibitor
ibrutinib
venetoclax
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1161254/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1161254/full

Similar Items